Randomized, Double Blind Phase II Study of FOLFOX/Bevacizumab Combined With MK-0646 Versus FOLFOX/Bevacizumab Combined With Placebo in First-Line Treatment of Metastatic Colorectal Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2011
At a glance
- Drugs Bevacizumab; Dalotuzumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- 24 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Aug 2010 New trial record